Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SYBX logo SYBX
Upturn stock ratingUpturn stock rating
SYBX logo

Synlogic Inc (SYBX)

Upturn stock ratingUpturn stock rating
$1.24
Last Close (24-hour delay)
Profit since last BUY2.48%
upturn advisory
Consider higher Upturn Star rating
BUY since 15 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: SYBX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $1

1 Year Target Price $1

Analysts Price Target For last 52 week
$1Target price
Low$0.9
Current$1.24
high$1.88

Analysis of Past Performance

Type Stock
Historic Profit -18.52%
Avg. Invested days 17
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.85M USD
Price to earnings Ratio 5.77
1Y Target Price 1
Price to earnings Ratio 5.77
1Y Target Price 1
Volume (30-day avg) 1
Beta 0.52
52 Weeks Range 0.90 - 1.88
Updated Date 07/1/2025
52 Weeks Range 0.90 - 1.88
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.22

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -14.07%
Return on Equity (TTM) 19.41%

Valuation

Trailing PE 5.77
Forward PE -
Enterprise Value -4005942
Price to Sales(TTM) 1652.07
Enterprise Value -4005942
Price to Sales(TTM) 1652.07
Enterprise Value to Revenue 0.35
Enterprise Value to EBITDA 0.18
Shares Outstanding 11696100
Shares Floating 3602752
Shares Outstanding 11696100
Shares Floating 3602752
Percent Insiders 11.31
Percent Institutions 64.74

Analyst Ratings

Rating 1
Target Price 1
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Synlogic Inc

stock logo

Company Overview

overview logo History and Background

Synlogic, Inc. is a biotechnology company founded in 2011. It focuses on developing Synthetic Biotic medicines to treat diseases. The company has evolved from a research-driven entity to a clinical-stage biopharmaceutical company.

business area logo Core Business Areas

  • Synthetic Biotic Medicines: Synlogic develops programmable, living medicines engineered to perform specific functions within the body to treat diseases. Their therapeutic pipeline focuses on metabolic and inflammatory diseases.

leadership logo Leadership and Structure

Dr. Aoife Brennan is the President and CEO. The company has a board of directors and a management team overseeing research, development, and operations.

Top Products and Market Share

overview logo Key Offerings

  • SYNB1934 (Phenylketonuria - PKU): An investigational Synthetic Biotic medicine designed to lower levels of phenylalanine (Phe) in patients with PKU. It is currently in clinical trials. No definitive market share data is available as it is not yet approved. Competitors include BioMarin Pharmaceutical Inc. (BMN).
  • SYNB8802 (Enteric Hyperoxaluria): An investigational Synthetic Biotic medicine designed to address enteric hyperoxaluria. It is in clinical development. No market share data is available as it is not yet approved. Competitors include Dicerna Pharmaceuticals (acquired by Novo Nordisk).

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The synthetic biology subsector is rapidly growing with increasing potential for treating a wide array of diseases.

Positioning

Synlogic is a pioneer in the field of Synthetic Biotic medicines, differentiating itself through its proprietary platform. Its competitive advantage lies in its ability to engineer microbes with specific therapeutic functions. However, the company's early stage development pipeline presents risks.

Total Addressable Market (TAM)

The TAM for Synlogic's focus areas such as PKU and hyperoxaluria is significant and growing, potentially reaching multi-billion dollars. Synlogic is positioning itself to capture a portion of this market through its novel therapeutic approach.

Upturn SWOT Analysis

Strengths

  • Proprietary Synthetic Biotic platform
  • Novel approach to treating diseases
  • Experienced management team
  • Strong intellectual property portfolio

Weaknesses

  • Early stage pipeline
  • High R&D costs
  • Dependence on clinical trial success
  • Limited commercialization experience

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline into new disease areas
  • Positive clinical trial results
  • Increased adoption of Synthetic Biotic medicines

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other biotechnology companies
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • BMN
  • NVO (post Dicerna acquisition)

Competitive Landscape

Synlogic's advantage lies in its unique Synthetic Biotic platform, but it faces strong competition from established pharmaceutical companies with greater resources and commercial experience.

Growth Trajectory and Initiatives

Historical Growth: Synlogic's growth has been primarily driven by its R&D efforts and clinical trial progress.

Future Projections: Future growth depends on the successful completion of clinical trials and potential partnerships. Analyst estimates vary widely due to the inherent risks in biotech development.

Recent Initiatives: Focus on advancing clinical programs for SYNB1934 and SYNB8802, exploring new therapeutic applications for its platform.

Summary

Synlogic is a promising early-stage biotech company pioneering Synthetic Biotic medicines. Its strengths lie in its innovative platform and experienced team. However, it faces significant risks associated with clinical trial success and competition. The company needs to carefully manage its resources and seek strategic partnerships to maximize its potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Publicly Available Information

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and is subject to change. Investing in biotechnology companies involves significant risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Synlogic Inc

Exchange NASDAQ
Headquaters Winchester, MA, United States
IPO Launch date 2015-10-01
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 1
Full time employees 1

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.